Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jul 20, 2023 10:00am
232 Views
Post# 35549584

RE:RE:RE:Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

RE:RE:RE:Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A July 20, 2023 - FTC and DOJ Release New Draft Merger Guidelines

"The draft outlines 13 principles for reviewing merger analysis, with one key principle stating that mergers should not substantially increase concentration in already highly saturated markets."

" ..
the new guidelines released by the FTC and DOJ cover both horizontal and vertical mergers and represent a significant overhaul of the previous guidelines."

[New guidelines could materially impact the Pfizer US$43 Billion planned acquisition of ADC company Seagen counter to Pfizer's position ]


https://www.biospace.com/article/ftc-department-of-justice-release-new-draft-merger-guidelines/

July 20, 2023 - FTC and Amgen break off settlement talks over Horizon.

https://www.biospace.com/article/ftc-amgen-break-off-settlement-talks-over-horizon-deal/
<< Previous
Bullboard Posts
Next >>